Salix Pharmaceuticals Ltd. (SLXP) said the U.S. Food and Drug Administration or FDA issued a Complete Response Letter or CRL on March 7, 2011 for the supplemental New Drug Application or sNDA for XIFAXAN 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome or Non-C IBS and IBS-related bloating.
The company added that CRL reconfirms its understanding that the FDA deems the XIFAXAN 550 mg sNDA for non-C IBS is not ready for approval primarily due to a newly expressed need for retreatment information. The company received the CRL at around 8:00 p.m. ET on Monday, March 7, 2011.
During this time, the company plans to request a Type A meeting with the Agency to discuss the XIFAXAN 550 mg sNDA for non-C IBS and also intends to provide its next update during its first quarter 2011 earnings call to be scheduled for early May 2011.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.